GlassScriptPhysician profile
Sahar Sheikhbahaei
NPI 1023464153
$4,372.49
in general payments reported to CMS, 2019-2025
34 companies · $2,425 in 2025
The $2,425 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.60 · 2023: $437 · 2024: $1,488 · 2025: $2,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,321 · Education: $28.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,321.26 |
| Education | $28.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $952.13 | 2023-2025 | Rystiggo, Zilbrysq, Fintepla |
| Abbvie INC. | $560.16 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $329.36 | 2024-2025 | Ultomiris |
| Lilly USA, LLC | $272.92 | 2023-2025 | Kisunla, Emgality, Reyvow |
| Pfizer INC. | $257.79 | 2024-2025 | |
| Celgene Corporation | $184.69 | 2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $167.52 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Jazz Pharmaceuticals INC. | $163.86 | 2023-2025 | Xywav |
| Axsome Therapeutics, INC. | $140.65 | 2023-2025 | Symbravo, Sunosi |
| Neurelis, INC. | $117.92 | 2023-2025 | Valtoco |
| Biogen, INC. | $111.18 | 2024-2025 | Skyclarys, Spinraza, Qalsody |
| Grifols USA, LLC | $99.87 | 2024-2025 | Gamunex-C |
| Acadia Pharmaceuticals INC | $93.44 | 2024-2025 | Daybue |
| Amgen INC. | $88.82 | 2025 | Uplizna |
| Harmony Biosciences LLC | $83.62 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $80.88 | 2024-2025 | Wainua |
| Inspire Medical Systems, INC. | $75.35 | 2025 | Inspire |
| Argenx US, INC. | $56.58 | 2025 | Vyvgart Hytrulo |
| Xeris Pharmaceuticals, INC. | $52.32 | 2023-2025 | Keveyis |
| Avadel Cns Pharmaceuticals, LLC | $51.19 | 2024 | Lumryz |
| Tanabe Pharma America, INC. | $49.21 | 2022-2025 | Radicava |
| Janssen Biotech, INC. | $48.58 | 2025 | |
| Kyowa Kirin, INC. | $41.73 | 2024-2025 | Nourianz |
| Alnylam Pharmaceuticals INC. | $36.68 | 2024-2025 | Amvuttra |
| Sk Life Science, INC. | $34.96 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.73 | 2024 | Hyqvia |
| Lundbeck LLC | $31.69 | 2025 | Vyepti |
| Tonix Medicines, INC. | $25.98 | 2025 | Zembrace Symtouch |
| Ge Healthcare | $24.14 | 2025 | |
| Amneal Pharmaceuticals LLC | $24.05 | 2023 | Rytary |
| Neuropace, INC. | $22.67 | 2025 | |
| Eisai INC. | $22.04 | 2024 | |
| Genentech USA, INC. | $21.55 | 2024 | Ocrevus |
| Genzyme Corporation | $16.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sahar Sheikhbahaei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.